Brief: Renovorx Achieves Major Milestone With Full Enrollment In Phase Iii Tiger-Pac Trial For Locally Advanced Pancreatic Cancer
11/08/2026 14:25
BRIEF-Renovorx Achieves Major Milestone With Full Enrollment In Phase Iii Tiger-Pac Trial For Locally Advanced Pancreatic Cancer Aug 11 (Reuters) - RenovoRx Inc RNXT.O:
RENOVORX ACHIEVES MAJOR MILESTONE WITH FULL ENROLLMENT IN PHASE III TIGER-PAC TRIAL FOR LOCALLY ADVANCED PANCREATIC CANCER
RENOVORX - TRIAL COMPLETION EXPECTED H1 2027; TOP LINE DATA EXPECTED H2 2027
Source text: ID:nGNXcdd0cb
Further company coverage: RNXT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RenovoRx
See all newsBrief: Renovorx Advances Tamp Into Borderline Resectable Pancreatic Cancer With First Patient Enrolled In Investigator-Initiated Prism-Tamp Trial
RenovoRx Inc reports results for the quarter ended June 30 - Earnings Summary
Oncology device maker RenovoRx's Q2 revenue surges, raises FY outlook
Brief: RenovoRx Q2 Net Income USD -2.911 Million
Brief: Renovorx Achieves Major Milestone With Full Enrollment In Phase Iii Tiger-Pac Trial For Locally Advanced Pancreatic Cancer